Deletion of Phe508 (ΔF508) in the first nucleotide-binding domain (NBD1) of CFTR causes cystic fibrosis. The mutation severely reduces the stability and folding of the protein by disrupting interactions between NBD1 and the second transmembrane domain (TMD2). We found that replacement of Val510 with acidic residues (but not neutral or positive residues) promoted maturation of ΔF508-CFTR with V510D more efficiently than V510E. Promotion of ΔF508-CFTR maturation did not require NBD2 as introduction of V510D into a ΔNBD2/ΔF508-CFTR mutant restored maturation to levels similar to that of full-length protein. The V510D mutation increased the half-life of mature ΔF508-CFTR at the cell surface by about 5-fold to resemble the half-life of wild-type CFTR. It was also observed that introduction of the V510R/R1070D mutations into ΔF508-CFTR also promoted maturation whereas the V510D/R1070A mutations did not. We propose that the V510D mutation in NBD1 promotes maturation and stabilizes ΔF508-CFTR at the cell surface through formation of a salt bridge with Arg1070 in TMD2.
This work was supported by a grant from the Canadian Institutes for Health Research (Grant 62832). D.M.C. is the recipient of the Canadian Research Chair in Membrane Biology.
The cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP-regulated chloride channel that is located on the apical surface of epithelial cells that line lung airways and ducts of various glands (reviewed in ref (
Cystic fibrosis (CF) is caused by mutations that impair synthesis and trafficking of the protein ( Abbreviations: TM, transmembrane; NBD, nucleotide-binding domain; HEK, human embryonic kidney; BHK, baby hamster kidney.
A treatment for CF would be to promote folding of ΔF508-CFTR to increase the amount delivered to the cell surface because ΔF508-CFTR retains some functional activity (
Characterization of suppressor mutations could provide useful information needed to develop therapeutic strategies to repair ΔF508-CFTR. The V510D suppressor mutation is interesting because Val510 is predicted to reside at the domain−domain interface between NBD1 and TMD2 in close proximity to Phe508 (
Mutations were introduced into ΔF508-CFTR, ΔF508/ΔNBD2 (Δ1173−1480)-CFTR, or ΔF508/ΔNBD2 (Δ1197−1480)-CFTR cDNAs containing an A52 epitope tag at the C-terminal end (
HEK 293 cells were transfected with W356C/W1145C-, ΔF508/W356C/W1145C-, or ΔF508/V510D/W356C/W1145C-CFTR cDNAs, and the cells were incubated for 4 h at 37 °C. The transfection medium was removed, and the cells were incubated in fresh medium overnight at 30 °C. The cells were then treated for 15 min at 20 °C with 3 μM BMH. The medium was removed, and fresh medium containing 0.1 mM cysteine was added. At various time points the cells were cooled on ice, harvested, and washed with PBS, and whole cell SDS extracts were prepared. The reaction mixtures were then subjected to SDS−PAGE (6.5% (w/v) polyacrylamide gels) and immunoblot analysis with a rabbit polyclonal antibody against CFTR (
Pulse−chase experiments (
Measurement of cAMP-stimulated iodide efflux was performed on baby hamster kidney (BHK) cells or BHK cells expressing wild-type or mutant ΔF508/V510D-CFTRs as described previously (
Models of CFTR structure predict that the segment in NBD1 containing Phe508 to Val510 would lie close to the fourth intracellular loop (ICL4) in TMD2 that connects transmembrane segments 10 and 11 (Figure
Effect of charged amino acids at position Val510 at the NBD1−TMD2 interface on maturation of ΔF508-CFTR. Amino acids located at the NBD1−TMD2 (ICL4) interface in models of CFTR (A (
It was possible that the high level of expression of V510D/ΔF508 in the transiently transfected HEK 293 cells was also a factor in enhancing maturation of the mutant. To examine the extent of maturation at lower levels of expression, HEK 293 cells were transfected with lower concentrations of plasmid containing V510D/ΔF508 cDNA and whole cell extracts subjected to immunoblot analysis 42 h after transfection. The time of incubation was increased so CFTR could be detected after transfection with low cDNA concentrations. It was observed that expression of CFTR was reduced when cells were transfected with lower concentrations of plasmid (Figure
To test if the mutant was active, BHK cell lines were generated that stably expressed wild-type or V510D/ΔF508-CFTRs for use in iodide efflux assays. The relative expression level of mature to total CFTR for mutant V510D/ΔF508 in BHK cells was also found to be about 50% (data not shown). Iodide efflux assays were performed rather than chloride channel measurements because very few channels other than CFTR can conduct iodide ions (
Iodide efflux activity of wild-type and ΔF508/V510D-CFTR. Iodide efflux assays were performed on BHK cells stably expressing wild-type CFTR, mutant ΔF508/V510D, or no CFTR (control). At time 0, forskolin was added to start stimulation of the iodide-loaded cells. Each value is the mean ± SD (
Wild-type CFTR lacking NBD2 shows efficient maturation (
Effect of V510D on maturation of ΔF508/ΔNBD2 mutants. Immunoblots of HEK 293 cells expressing A52-tagged CFTR mutants lacking NBD2 that were truncated after residue 1196 (Δ1197−1480) or 1172 (Δ1173−1480). The positions of mature and immature ΔNBD2-CFTRs are indicated.
These results suggest that the V510D suppressor mutation differs from other NBD1 suppressor mutations because the absence of NBD2 did not reduce its effect. A potential problem with this interpretation, however, is that the two studies used different ΔF508/ΔNBD2 constructs. This study used a construct truncated after residue 1196 (Δ1197−1480) whereas the other study used a construct truncated after residue 1172 (Δ1173−1480) (
It was predicted in a modeling study (
Effect of Arg1070 and Val510 mutations on maturation of ΔF508-CFTR. Whole cell immunoblots were performed on HEK 293 cells that were transfected with the indicated ΔF508-CFTR mutants and incubated for 18 h at 37 °C (A, C, D) or 30 °C (B). The positions of mature and immature CFTRs are indicated.
Mutant ΔF508/V510R/R1070D was constructed to reverse the positions of the charged residues. Figure
The ΔF508 mutation reduces the stability of CFTR at the cell surface (
Measurement of cell surface stability by cross-linking assay. HEK 293 cells expressing wild-type, ΔF508-, or ΔF508/V510D-CFTRs containing the W356C and W1145C cysteines were treated with the thiol cross-linker BMH. The cross-linker was then removed at time 0, and whole cell extracts were subjected to immunoblot analysis at the indicated times (A), and the level of cross-linked CFTR remaining at each time point was quantitated (B). The positions of immature, mature, and cross-linked (X-link) forms of CFTR are indicated.
A potential problem with the cross-linking assay is that it required introduction of a pair of cysteines into the TM segments of CFTR. It was possible that cysteines W356C and W1145C may influence the stability of the protein. To examine the effect of the V510D mutation on turnover of ΔF508-CFTR without the introduced cysteines, a pulse−chase assay was performed. It was observed that the rate of conversion of immature wild-type CFTR to the mature form was nearly complete by 2−4 h (Figure
Metabolic labeling of CFTR. HEK 293 cells were transfected with A52-tagged wild-type, ΔF508, or ΔF508/V510D cDNAs. After 24 h, the cells were pulse-labeled with [35S]-
After an 8 h chase, the majority of labeled CFTR in wild-type and mutant ΔF508/V510D was present as the mature protein (Figure
To test if V510D stabilizes ΔF508-CFTR at the cell surface, cells expressing wild-type, ΔF508-, or ΔF508/V510D-CFTRs were first incubated at 30 °C for 18 h so that ΔF508-CFTR would be present at the cell surface. CFTR at the cell surface was then biotinylated. The cells were washed to remove biotin-LC-hydrazide, and cells were harvested at various time points after labeling. Labeled CFTR was immunoprecipitated, samples were subjected to SDS−PAGE, and CFTR was detected with streptavidin conjugated to horseradish peroxidase. It was found that mature forms of wild-type or ΔF508/V510D-CFTRs had similar half-lives of about 12 h while ΔF508-CFTR had a short half-life of about 2 h (Figure
Cell surface labeling of CFTR. HEK 293 cells were transfected with the cDNAs of A52-tagged wild-type, ΔF508-, or ΔF508/V510D-CFTR. To compare the half-life of ΔF508-CFTR to wild-type or mutant ΔF508/V510D-CFTR, the cells were first incubated at 30 °C to promote maturation and increase the level of ΔF508-CFTR at the cell surface. After 18 h at 30 °C, cells were biotinylated. The biotin-LC-hydrazide was removed and replaced with fresh media. The cells were then harvested immediately (time 0) and at the indicated time points. The cells were solubilized and labeled CFTR collected by immunoprecipitation with monoclonal antibody A52. The samples were subjected to SDS−PAGE and CFTR detected with streptavidin conjugated to horseradish peroxidase followed by enhanced chemiluminescence. The position of mature CFTR is indicated.
The folding and trafficking defects of ΔF508-CFTR can be partially overcome by expressing the mutant at lower temperatures to yield a partially functional molecule at the cell surface (
A similar effect was observed when the combination of four NBD1 suppressor mutations (I539T, G550E, R553M, R555K) was introduced into ΔF508-CFTR (
Mutational analysis of Arg1070 in TMD2 yielded evidence that was consistent with the prediction that an aspartic acid introduced into position Val510 may stabilize ΔF508-CFTR through interactions with Arg1070. Mutation of Arg1070 to a neutral amino acid abolished V510D rescue of ΔF508-CFTR while V510R only rescued the mutant when the R1070D change was introduced (Figure
Comparison of the initial crystal structures of wild-type and ΔF508 NBD1s from CFTR suggested that the deletion only caused local structural changes restricted to residues 509−511 (
In this study we found that the ΔF508/V510D mutant was active while we failed to detect activity when V510D was introduced into Cys-less CFTR (
In summary, the V510D mutation increases the stability of ΔF508-CFTR by promoting NBD1−TMD2 interactions likely through formation of a salt bridge with Arg1070 in ICL4. A potential therapeutic strategy would be to mimic these effects using a compound that directly binds to the protein (pharmacological chaperone).